|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/inhibitor
|
 |
|
Title:
|
 |
Short form hgfa with first kunitz domain from hai-1
|
|
Structure:
|
 |
Hepatocyte growth factor activator. Chain: a. Fragment: sequence database residues 373-655. Synonym: hgf activator, hgfa. Engineered: yes. Kunitz-type protease inhibitor 1. Chain: i. Fragment: sequence database residues 245-303. Synonym: hepatocyte growth factor activator inhibitor type 1, hai-1,
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: hgfac. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: spint1, hai1. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.60Å
|
R-factor:
|
0.196
|
R-free:
|
0.218
|
|
|
Authors:
|
 |
S.Shia,J.Stamos,D.Kirchhofer,B.Fan,J.Wu,R.T.Corpuz,L.Santell, R.A.Lazarus,C.Eigenbrot
|
Key ref:
|
 |
S.Shia
et al.
(2005).
Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
J Mol Biol,
346,
1335-1349.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
21-Dec-04
|
Release date:
|
15-Feb-05
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
346:1335-1349
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
|
|
S.Shia,
J.Stamos,
D.Kirchhofer,
B.Fan,
J.Wu,
R.T.Corpuz,
L.Santell,
R.A.Lazarus,
C.Eigenbrot.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Hepatocyte growth factor activator (HGFA) is a serine protease that converts
hepatocyte growth factor (HGF) into its active form. When activated HGF binds
its cognate receptor Met, cellular signals lead to cell growth, differentiation,
and migration, activities which promote tissue regeneration in liver, kidney and
skin. Intervention in the conversion of HGF to its active form has the potential
to provide therapeutic benefit where HGF/Met activity is associated with
tumorigenesis. To help identify ways to moderate HGF/Met effects, we have
determined the molecular structure of the protease domain of HGFA. The structure
we determined, at 2.7 A resolution, with no pseudo-substrate or inhibitor bound
is characterized by an unconventional conformation of key residues in the enzyme
active site. In order to find whether this apparently non-enzymatically
competent arrangement would persist in the presence of a strongly-interacting
inhibitor, we also have determined, at 2.6 A resolution, the X-ray structure of
HGFA complexed with the first Kunitz domain (KD1) from the physiological
inhibitor hepatocyte growth factor activator inhibitor 1B (HAI-1B). In this
complex we observe a rearranged substrate binding cleft that closely mirrors the
cleft of other serine proteases, suggesting an extreme conformational dynamism.
We also characterize the inhibition of 16 serine proteases by KD1, finding that
the previously reported enzyme specificity of the intact extracellular region of
HAI-1B resides in KD1 alone. We find that HGFA, matriptase, hepsin, plasma
kallikrein and trypsin are potently inhibited, and use the complex structure to
rationalize the structural basis of these results.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Uninhibited HGFA. Schematic representation of the
crystallized HGFA 34 kDa fragment (starting at residue 373),
looking into the substrate binding/active site region. Disulfide
links are labeled. Cys168 was modeled with two side-chain
conformations, only one of which makes a bond to Cys182. Cys187
is unpaired. An eight-residue section of the HGFA light chain
(green) can be seen in the rear, including its disulfide link to
the protease domain (Cys394/Cys122). Loops colored pink differ
structurally among homologous enzymes and help determine
inhibitor and substrate specificity. The crystallized construct
in the context of intact HGFA is depicted at the bottom.
Molecular images produced using PyMOL (Delano Scientific, San
Carlos CA).
|
 |
Figure 5.
Figure 5. The HGFA/KD1 complex. (a) The conventional
conformation of the HGFA substrate binding region from the
HAI-1-KD1 complex (light brown) compared to the unconventional
conformation from uninhibited HGFA (blue). (b) Overall view with
HGFA surface (light brown/red) and KD1 (green/yellow), including
side-chains form Arg13(258), Arg15(260), and Phe18(263). The
(N-terminal affinity tag + KD1) construct in the context of
HAI-1B is depicted at the bottom. Prominent residues from the
HGFA 37-loop, 60-loop and 99-loop are labeled. Red and yellow
colors are residues of HGFA (red) and KD1 (yellow) with an atom
within 3.5 Å of the other protein. (c) Details of the
interaction between HGFA and HAI-1-KD1, in the same orientation
as above. Portions of the KD1 domain (yellow) are depicted in
the HGFA (light brown) active site. H-bonds between KD1 and HGFA
are grey/black dotted lines. Inhibitor residue labels are
underlined.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2005,
346,
1335-1349)
copyright 2005.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Tripathi,
A.A.Potdar,
H.Yamashita,
B.Weidow,
P.T.Cummings,
D.Kirchhofer,
and
V.Quaranta
(2011).
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
|
| |
Prostate,
71,
184-196.
|
 |
|
|
|
|
 |
A.D.Vogt,
A.Bah,
and
E.Di Cera
(2010).
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa.
|
| |
J Phys Chem B,
114,
16125-16130.
|
 |
|
|
|
|
 |
C.Eigenbrot,
R.Ganesan,
and
D.Kirchhofer
(2010).
Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
|
| |
FEBS J,
277,
2215-2222.
|
 |
|
|
|
|
 |
R.Ganesan,
C.Eigenbrot,
and
D.Kirchhofer
(2010).
Structural and mechanistic insight into how antibodies inhibit serine proteases.
|
| |
Biochem J,
430,
179-189.
|
 |
|
|
|
|
 |
Z.Chen,
L.A.Pelc,
and
E.Di Cera
(2010).
Crystal structure of prethrombin-1.
|
| |
Proc Natl Acad Sci U S A,
107,
19278-19283.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Bah,
C.J.Carrell,
Z.Chen,
P.S.Gandhi,
and
E.Di Cera
(2009).
Stabilization of the E* form turns thrombin into an anticoagulant.
|
| |
J Biol Chem,
284,
20034-20040.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Giubellino,
W.M.Linehan,
and
D.P.Bottaro
(2009).
Targeting the Met signaling pathway in renal cancer.
|
| |
Expert Rev Anticancer Ther,
9,
785-793.
|
 |
|
|
|
|
 |
E.Di Cera
(2009).
Serine proteases.
|
| |
IUBMB Life,
61,
510-515.
|
 |
|
|
|
|
 |
P.S.Gandhi,
M.J.Page,
Z.Chen,
L.Bush-Pelc,
and
E.Di Cera
(2009).
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A.
|
| |
J Biol Chem,
284,
24098-24105.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Ganesan,
C.Eigenbrot,
Y.Wu,
W.C.Liang,
S.Shia,
M.T.Lipari,
and
D.Kirchhofer
(2009).
Unraveling the allosteric mechanism of serine protease inhibition by an antibody.
|
| |
Structure,
17,
1614-1624.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Désilets,
F.Béliveau,
G.Vandal,
F.O.McDuff,
P.Lavigne,
and
R.Leduc
(2008).
Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.
|
| |
J Biol Chem,
283,
10535-10542.
|
 |
|
|
|
|
 |
K.Sexton,
D.Balharry,
and
K.A.BéruBé
(2008).
Genomic biomarkers of pulmonary exposure to tobacco smoke components.
|
| |
Pharmacogenet Genomics,
18,
853-860.
|
 |
|
|
|
|
 |
M.Tripathi,
S.Nandana,
H.Yamashita,
R.Ganesan,
D.Kirchhofer,
and
V.Quaranta
(2008).
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
|
| |
J Biol Chem,
283,
30576-30584.
|
 |
|
|
|
|
 |
R.E.Saunders,
C.Abarrategui-Garrido,
V.Frémeaux-Bacchi,
E.Goicoechea de Jorge,
T.H.Goodship,
M.López Trascasa,
M.Noris,
I.M.Ponce Castro,
G.Remuzzi,
S.Rodríguez de Córdoba,
P.Sánchez-Corral,
C.Skerka,
P.F.Zipfel,
and
S.J.Perkins
(2007).
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
|
| |
Hum Mutat,
28,
222-234.
|
 |
|
|
|
|
 |
Y.Wu,
C.Eigenbrot,
W.C.Liang,
S.Stawicki,
S.Shia,
B.Fan,
R.Ganesan,
M.T.Lipari,
and
D.Kirchhofer
(2007).
Structural insight into distinct mechanisms of protease inhibition by antibodies.
|
| |
Proc Natl Acad Sci U S A,
104,
19784-19789.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Parr,
and
W.G.Jiang
(2006).
Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
|
| |
Int J Cancer,
119,
1176-1183.
|
 |
|
|
|
|
 |
P.Moran,
W.Li,
B.Fan,
R.Vij,
C.Eigenbrot,
and
D.Kirchhofer
(2006).
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
|
| |
J Biol Chem,
281,
30439-30446.
|
 |
|
|
|
|
 |
B.Fan,
T.D.Wu,
W.Li,
and
D.Kirchhofer
(2005).
Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin.
|
| |
J Biol Chem,
280,
34513-34520.
|
 |
|
|
|
|
 |
B.S.Knudsen,
J.M.Lucas,
L.Fazli,
S.Hawley,
S.Falcon,
I.M.Coleman,
D.B.Martin,
C.Xu,
L.D.True,
M.E.Gleave,
P.S.Nelson,
and
G.E.Ayala
(2005).
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.
|
| |
Am J Pathol,
167,
255-266.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |